⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8704067 | 0.69 | BRD4 (0.40) | — | |
| Methylpyrrolidone SCHEMBL9504181 | 0.67 | BRD4 (0.85) | — | |
| SCHEMBL8682109 | 0.66 | BRD4 (0.38) | — | |
| SCHEMBL8683163 | 0.66 | RAB9A (0.39) | — | |
| SCHEMBL14191803 | 0.64 | — | — | |
| SCHEMBL3557350 | 0.63 | — | — | |
| SCHEMBL208037 | 0.63 | — | — | |
| Methylpyrrolidone SCHEMBL28183883 | 0.62 | — | — | |
| SCHEMBL2887325 | 0.61 | — | — | |
| SCHEMBL8433311 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | claimed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | claimed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | claimed |
| US-20220054491-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| US-20220054492-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | claimed |
| EP-3890716-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| US-20210230170-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | claimed |
| EP-3849534-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | claimed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | claimed |
| WO-2020055756-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020055760-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020055755-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020055758-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020055761-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | claimed |